These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

178 related items for PubMed ID: 16384948

  • 1. Inhibition of PKC beta by oral administration of ruboxistaurin is well tolerated and ameliorates diabetes-induced retinal hemodynamic abnormalities in patients.
    Aiello LP, Clermont A, Arora V, Davis MD, Sheetz MJ, Bursell SE.
    Invest Ophthalmol Vis Sci; 2006 Jan; 47(1):86-92. PubMed ID: 16384948
    [Abstract] [Full Text] [Related]

  • 2. Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C beta-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial.
    Vinik AI, Bril V, Kempler P, Litchy WJ, Tesfaye S, Price KL, Bastyr EJ, MBBQ Study Group.
    Clin Ther; 2005 Aug; 27(8):1164-80. PubMed ID: 16199243
    [Abstract] [Full Text] [Related]

  • 3. Effect of ruboxistaurin in patients with diabetic macular edema: thirty-month results of the randomized PKC-DMES clinical trial.
    PKC-DMES Study Group.
    Arch Ophthalmol; 2007 Mar; 125(3):318-24. PubMed ID: 17353401
    [Abstract] [Full Text] [Related]

  • 4. A 6-month, randomized, double-masked, placebo-controlled study evaluating the effects of the protein kinase C-beta inhibitor ruboxistaurin on skin microvascular blood flow and other measures of diabetic peripheral neuropathy.
    Casellini CM, Barlow PM, Rice AL, Casey M, Simmons K, Pittenger G, Bastyr EJ, Wolka AM, Vinik AI.
    Diabetes Care; 2007 Apr; 30(4):896-902. PubMed ID: 17392551
    [Abstract] [Full Text] [Related]

  • 5. Oral protein kinase c β inhibition using ruboxistaurin: efficacy, safety, and causes of vision loss among 813 patients (1,392 eyes) with diabetic retinopathy in the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study and the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study 2.
    Aiello LP, Vignati L, Sheetz MJ, Zhi X, Girach A, Davis MD, Wolka AM, Shahri N, Milton RC, PKC-DRS and PKC-DRS2 Study Groups.
    Retina; 2011 Nov; 31(10):2084-94. PubMed ID: 21862954
    [Abstract] [Full Text] [Related]

  • 6. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy.
    PKC-DRS2 GroupBeetham Eye Institute, Joslin Diabetes Center, 1 Joslin Place, Boston, MA 02215, USA. LPAiello@Joslin.Harvard.edu, Aiello LP, Davis MD, Girach A, Kles KA, Milton RC, Sheetz MJ, Vignati L, Zhi XE.
    Ophthalmology; 2006 Dec; 113(12):2221-30. PubMed ID: 16989901
    [Abstract] [Full Text] [Related]

  • 7. Endothelial and neural regulation of skin microvascular blood flow in patients with diabetic peripheral neuropathy: effect of treatment with the isoform-specific protein kinase C beta inhibitor, ruboxistaurin.
    Brooks B, Delaney-Robinson C, Molyneaux L, Yue DK.
    J Diabetes Complications; 2008 Dec; 22(2):88-95. PubMed ID: 18280438
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Specific retinal diacylglycerol and protein kinase C beta isoform modulation mimics abnormal retinal hemodynamics in diabetic rats.
    Bursell SE, Takagi C, Clermont AC, Takagi H, Mori F, Ishii H, King GL.
    Invest Ophthalmol Vis Sci; 1997 Dec; 38(13):2711-20. PubMed ID: 9418723
    [Abstract] [Full Text] [Related]

  • 10. Effect of ruboxistaurin on the visual acuity decline associated with long-standing diabetic macular edema.
    Davis MD, Sheetz MJ, Aiello LP, Milton RC, Danis RP, Zhi X, Girach A, Jimenez MC, Vignati L, PKC-DRS2 Study Group.
    Invest Ophthalmol Vis Sci; 2009 Jan; 50(1):1-4. PubMed ID: 18708615
    [Abstract] [Full Text] [Related]

  • 11. The effect of the oral PKC β inhibitor ruboxistaurin on vision loss in two phase 3 studies.
    Sheetz MJ, Aiello LP, Davis MD, Danis R, Bek T, Cunha-Vaz J, Shahri N, Berg PH, MBDL and MBCU Study Groups.
    Invest Ophthalmol Vis Sci; 2013 Mar 11; 54(3):1750-7. PubMed ID: 23404115
    [Abstract] [Full Text] [Related]

  • 12. PKC-beta inhibitor (LY333531) attenuates leukocyte entrapment in retinal microcirculation of diabetic rats.
    Nonaka A, Kiryu J, Tsujikawa A, Yamashiro K, Miyamoto K, Nishiwaki H, Honda Y, Ogura Y.
    Invest Ophthalmol Vis Sci; 2000 Aug 11; 41(9):2702-6. PubMed ID: 10937586
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
    Bergman AJ, Stevens C, Zhou Y, Yi B, Laethem M, De Smet M, Snyder K, Hilliard D, Tanaka W, Zeng W, Tanen M, Wang AQ, Chen L, Winchell G, Davies MJ, Ramael S, Wagner JA, Herman GA.
    Clin Ther; 2006 Jan 11; 28(1):55-72. PubMed ID: 16490580
    [Abstract] [Full Text] [Related]

  • 14. Effect of ruboxistaurin on blood-retinal barrier permeability in relation to severity of leakage in diabetic macular edema.
    Strøm C, Sander B, Klemp K, Aiello LP, Lund-Andersen H, Larsen M.
    Invest Ophthalmol Vis Sci; 2005 Oct 11; 46(10):3855-8. PubMed ID: 16186374
    [Abstract] [Full Text] [Related]

  • 15. Inhibition of PKC beta by ruboxistaurin does not enhance the acute blood pressure response to nitroglycerin.
    Benson C, Seger M, Voelker J.
    Clin Pharmacol Ther; 2007 Aug 11; 82(2):181-6. PubMed ID: 17443133
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized clinical trial.
    PKC-DRS Study Group.
    Diabetes; 2005 Jul 11; 54(7):2188-97. PubMed ID: 15983221
    [Abstract] [Full Text] [Related]

  • 18. Effect of ruboxistaurin on the visual acuity decline associated with long-standing diabetic macular edema.
    Sahu AK, Majji AB.
    Invest Ophthalmol Vis Sci; 2010 Dec 11; 51(12):6890; author reply 6890-1. PubMed ID: 21123772
    [No Abstract] [Full Text] [Related]

  • 19. Systemic hemodynamic function in humans with type 1 diabetes treated with protein kinase Cβ inhibition and renin-angiotensin system blockade: a pilot study.
    Cherney DZ, Reich HN, Scholey JW, Lai V, Slorach C, Zinman B, Bradley TJ.
    Can J Physiol Pharmacol; 2012 Jan 11; 90(1):113-21. PubMed ID: 22188532
    [Abstract] [Full Text] [Related]

  • 20. Clinical safety of the selective PKC-beta inhibitor, ruboxistaurin.
    McGill JB, King GL, Berg PH, Price KL, Kles KA, Bastyr EJ, Hyslop DL.
    Expert Opin Drug Saf; 2006 Nov 11; 5(6):835-45. PubMed ID: 17044810
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.